FDA panel recommends approval of COPD drug from GSK, Theravance

04/18/2013 | Bloomberg Businessweek

An FDA panel recommended approval of GlaxoSmithKline and Theravance's Breo Ellipta dry powder inhaler to address chronic obstructive pulmonary disease. The agency could decide on the drug's approval by May 12.

View Full Article in:

Bloomberg Businessweek

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT